Skeletal Muscle Loss During Treatment With Abiraterone in Patients With Metastatic Prostate Cancer
Conclusions: SMI decline occurs during AAP treatment for mHSPC and mCRPC, and is more pronounced in patients over 75 years old and those without previous local treatment. There was no statistically significant association between survival outcomes and SMI decline during AAP therapy.
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Prostate Cancer |
| Online Access: | http://dx.doi.org/10.1155/proc/1468262 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850141822302552064 |
|---|---|
| author | Eva Streckova Jiri Stejskal Daniela Kuruczova Adam Svobodnik Radka Stepanova Tomas Buchler |
| author_facet | Eva Streckova Jiri Stejskal Daniela Kuruczova Adam Svobodnik Radka Stepanova Tomas Buchler |
| author_sort | Eva Streckova |
| collection | DOAJ |
| description | Conclusions: SMI decline occurs during AAP treatment for mHSPC and mCRPC, and is more pronounced in patients over 75 years old and those without previous local treatment. There was no statistically significant association between survival outcomes and SMI decline during AAP therapy. |
| format | Article |
| id | doaj-art-e176156f39c4453e80b14f5e368e38cb |
| institution | OA Journals |
| issn | 2090-312X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Prostate Cancer |
| spelling | doaj-art-e176156f39c4453e80b14f5e368e38cb2025-08-20T02:29:18ZengWileyProstate Cancer2090-312X2025-01-01202510.1155/proc/1468262Skeletal Muscle Loss During Treatment With Abiraterone in Patients With Metastatic Prostate CancerEva Streckova0Jiri Stejskal1Daniela Kuruczova2Adam Svobodnik3Radka Stepanova4Tomas Buchler5Department of Oncology, Second Faculty of MedicineDepartment of Oncology, First Faculty of MedicineANOVA CRODepartment of Pharmacology, Faculty of MedicineDepartment of Pharmacology, Faculty of MedicineDepartment of Oncology, Second Faculty of MedicineConclusions: SMI decline occurs during AAP treatment for mHSPC and mCRPC, and is more pronounced in patients over 75 years old and those without previous local treatment. There was no statistically significant association between survival outcomes and SMI decline during AAP therapy.http://dx.doi.org/10.1155/proc/1468262 |
| spellingShingle | Eva Streckova Jiri Stejskal Daniela Kuruczova Adam Svobodnik Radka Stepanova Tomas Buchler Skeletal Muscle Loss During Treatment With Abiraterone in Patients With Metastatic Prostate Cancer Prostate Cancer |
| title | Skeletal Muscle Loss During Treatment With Abiraterone in Patients With Metastatic Prostate Cancer |
| title_full | Skeletal Muscle Loss During Treatment With Abiraterone in Patients With Metastatic Prostate Cancer |
| title_fullStr | Skeletal Muscle Loss During Treatment With Abiraterone in Patients With Metastatic Prostate Cancer |
| title_full_unstemmed | Skeletal Muscle Loss During Treatment With Abiraterone in Patients With Metastatic Prostate Cancer |
| title_short | Skeletal Muscle Loss During Treatment With Abiraterone in Patients With Metastatic Prostate Cancer |
| title_sort | skeletal muscle loss during treatment with abiraterone in patients with metastatic prostate cancer |
| url | http://dx.doi.org/10.1155/proc/1468262 |
| work_keys_str_mv | AT evastreckova skeletalmusclelossduringtreatmentwithabirateroneinpatientswithmetastaticprostatecancer AT jiristejskal skeletalmusclelossduringtreatmentwithabirateroneinpatientswithmetastaticprostatecancer AT danielakuruczova skeletalmusclelossduringtreatmentwithabirateroneinpatientswithmetastaticprostatecancer AT adamsvobodnik skeletalmusclelossduringtreatmentwithabirateroneinpatientswithmetastaticprostatecancer AT radkastepanova skeletalmusclelossduringtreatmentwithabirateroneinpatientswithmetastaticprostatecancer AT tomasbuchler skeletalmusclelossduringtreatmentwithabirateroneinpatientswithmetastaticprostatecancer |